[1] Staunton M, Dodd JD, McCormick PA, et al. Finding evidence-based answers to practical questions in radiology:which patients with inoperable hepatocellular carcinoma will survive longer afte transarterial chemoembolization?. Radiology, 2005, 237(2):404-413.
[2] Carr BI. Hepatocellular carcinoma:current management and futuret rends. Gastroenterology, 2004, 127(5 Suppl 1):S218-S224.
[3] Berdonosov SS, Berdonosova DG, Znamenskaya NV. Sorption of 90Sr and 90Y with the vaterite modification of calcium carbonate.Radiochemistry, 2003, 45(6):613-615.
[4] Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med, 1997,24(3):293-298.
[5] Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases:comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med, 2004, 45(11):1892-1897.
[6] Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (Thera-Sphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol, 2004, 15(4):335-345.
[7] Cao X, He N, Sun J, et al. Hepatic mdioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer. Chin Med J (Engl), 1999, 112(5):430-432.
[8] Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y microspheres. J Nucl Med, 2000, 41(10):1673-1681.
[9] Sarfaraz M, Kennedy AS, Lodge MA, et al. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys, 2004, 31(9):2449-2453.
[10] Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90)Y microspheres in man:review of four explanted whole livers. Int J Radiat Oncol Biol Phys, 2004, 60(5):1552-1563.
[11] Leung DA, Coin JE, Sickles C, et al. Determinants of postembolization syndrome following hepatic chemoembolization. J Vase Interv Radiol, 2001, 12(3):321-326.
[12] Salem R, Thurston KG, Carr BI, et al. Yttrium-90 microspheres:radiation therapy for unresectable liver cancer. J Vasc Interv Radiol, 2002, 13(9 Pt 2):S223-S229.
[13] Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microsphere (Thera-Sphere):safety, tumor response, and survival. J Vasc Interv Radiol,2005, 16(12):1627-1639.
[14] Ahmad J, Bhee J, Carr BI. The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinomal. Dig Dis Sic, 2005, 50(2):331-335.
[15] Ebied OM, Federle MP, Cart BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer, 2003, 97(4):1042-1050.
[16] Carr BI-Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma:interim safety and survival data on 65 patients. Liver Transpl, 2004, 10(2 Suppl 1):S107-S110.
[17] Geschwind JF, Salem R Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology,2004, 127(Ssupp11):S194-S205.
[18] Lee HS, KIm JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemcembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. Cancer,1997, 79(11):2087-2094.